ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma

Fan, Wenhua; Wang, Di; Li, Guanzhang; Xu, Jianbao; Ren, Changyuan; Sun, Zhiyan; Wang, Zhiliang; Ma, Wenping; Zhao, Zheng; Bao, Zhaoshi; Jiang, Tao*; Zhang, Ying*哈尔滨医科大学; y
CNS Neuroscience & Therapeutics2022-12DOI: 10.1111/cns.13944
9阅读
引用收藏
分享

摘要

Aims Gliomas are the primary malignant brain tumor and characterized as the striking cellular heterogeneity and intricate tumor microenvironment (TME), where chemokines regulate immune cell trafficking by shaping local networks. This study aimed to construct a chemokine-based gene signature to evaluate the prognosis and therapeutic response in glioma. Methods In this study, 1024 patients (699 from TCGA and 325 from CGGA database) with clinicopathological information and mRNA sequencing data were enrolled. A chemokine gene signature was constructed by combining LASSO and SVM-RFE algorithm. GO, KEGG, and GSVA analyses were performed for function annotations of the chemokine signature. Candidate mRNAs were subsequently verified through qRT-PCR in an independent cohort including 28 glioma samples. Then, through immunohistochemical staining (IHC), we detected the expression of immunosuppressive markers and explore the role of this gene signature in immunotherapy for glioma. Lastly, the Genomics of Drug Sensitivity in Cancer (GDSC) were leveraged to predict the potential drug related to the gene signature in glioma. Results A constructed chemokine gene signature was significantly associated with poorer survival, especially in glioblastoma, IDH wildtype. It also played an independent prognostic factor in both datasets. Moreover, biological function annotations of the predictive signature indicated the gene signature was positively associated with immune-relevant pathways, and the immunosuppressive protein expressions (PD-L1, IBA1, TMEM119, CD68, CSF1R, and TGFB1) were enriched in the high-risk group. In an immunotherapy of glioblastoma cohort, we confirmed the chemokine signature showed a good predictor for patients' response. Lastly, we predicted twelve potential agents for glioma patients with higher riskscore. Conclusion In all, our results highlighted a potential 4-chemokine signature for predicting prognosis in glioma and reflected the intricate immune landscape in glioma. It also threw light on integrating tailored risk stratification with precision therapy for glioblastoma.

学科与关键词

关键词
chemokinegliomaimmunotherapyprognostic signaturetumor microenvironment
相关
加载中…
  • Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma
    Zhang, Sibin; Xiao, Xu; Wang, Yu; Song, Tianjun; Li, Chenlong; Bao, Hongbo; Liu, Qing; Sun, Guiyin; Sun, Xiaoyang; Su, Tianqi; Fu, Tianjiao; Wang, Yujie; Liang, Peng*Frontiers in Genetics, 2022, 13: 899125.被引 2
  • Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
    Zhang, Chunlong; Zhang, Yuxi; Tan, Guiyuan; Mi, Wanqi; Zhong, Xiaoling; Zhang, Yu; Zhao, Ziyan; Li, Feng*; Xu, Yanjun*; Zhang, Yunpeng*Frontiers in Immunology, 2022, 13: 853074.被引 1
  • Identification of a single cell-based signature for predicting prognosis risk and immunotherapy response in patients with glioblastoma
    Dai, Ziyu; Zhang, Nan; Zhou, Ran; Zhang, Hao; Zhang, Liyang; Wang, Zeyu; Zeng, Wenjing; Luo, Peng; Zhang, Jian; Liu, Zhixiong*; Cheng, Quan*Clinical Immunology, 2023, 251: 109345.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
CNS Neuroscience & Therapeutics
发表日期
2022-12
卷期
第 28 卷, 第 12 期
页码
2090-2103
DOI
10.1111/cns.13944
语言
ENGLISH
成果收录
SCIE · PUBMED
资助标注
Beijing Municipal Administration of Hospitals' Mission Plan [SML20180501]; Beijing Postdoctoral Research Foundation [2021-ZZ-022]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-021]; China Postdoctoral Science Foundation [2021M702308, 2022M712218]; National Natural Science Foundation of China [81972337, 81761168038]; Natural Science Foundation of Beijing Municipality [JQ20030]; public welfare development and reform pilot project of Beijing Medical Research Institute [JYY 2019-5]; Beijing Natural Science Foundation [7222018]

作者

  • F

    Fan, Wenhua (第一作者)

    capital med univ · beijing neurosurg inst

  • W

    Wang, Di

    capital med univ

查看全部 12 位作者收起作者
  • L

    Li, Guanzhang

    capital med univ · beijing neurosurg inst

  • X

    Xu, Jianbao

    2 · harbin med univ

  • R

    Ren, Changyuan

    capital med univ

  • S

    Sun, Zhiyan

    beijing neurosurg inst · capital med univ

  • W

    Wang, Zhiliang

    capital med univ

  • M

    Ma, Wenping

    beijing neurosurg inst · capital med univ

  • Z

    Zhao, Zheng

    beijing neurosurg inst · capital med univ

  • B

    Bao, Zhaoshi

    beijing neurosurg inst · capital med univ

  • J

    Jiang, Tao (通讯)

    beijing neurosurg inst · capital med univ

  • Z

    Zhang, Ying (通讯)

    beijing neurosurg inst · capital med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417